相似文献
1
IL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy?
Oncoimmunology. 2015 Nov 3;5(3):e1102829. doi: 10.1080/2162402X.2015.1102829. eCollection 2016 Mar.
2
Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera.
Immunol Lett. 2014 May-Jun;159(1-2):1-10. doi: 10.1016/j.imlet.2014.01.017. Epub 2014 Feb 7.
3
In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.
J Immunol. 2009 Oct 15;183(8):4904-12. doi: 10.4049/jimmunol.0900284.
4
Antitumor activity of IL-2/anti-IL-2 mAb immunocomplexes exerts synergism with that of N-(2-hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugate due to its low immunosuppressive activity.
Int J Cancer. 2011 Oct 15;129(8):2002-12. doi: 10.1002/ijc.25859. Epub 2011 Apr 13.
5
Chimera of IL-2 linked to light chain of anti-IL-2 mAb mimics IL-2/anti-IL-2 mAb complexes both structurally and functionally.
ACS Chem Biol. 2013 May 17;8(5):871-6. doi: 10.1021/cb3007242. Epub 2013 Mar 5.
6
Transient depletion of CD4(+) T cells augments IL-21-based immunotherapy of disseminated neuroblastoma in syngeneic mice.
Int J Cancer. 2010 Sep 1;127(5):1141-50. doi: 10.1002/ijc.25140.
7
Neutralization of interleukin-2 retards the growth of mouse renal cancer.
BJU Int. 2006 Jun;97(6):1314-21. doi: 10.1111/j.1464-410X.2006.06180.x.
8
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody.
Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):609-618. doi: 10.1073/pnas.1812186116. Epub 2018 Dec 26.
9
Prophylactic and Therapeutic Effects of Interleukin-2 (IL-2)/Anti-IL-2 Complexes in Systemic Lupus Erythematosus-Like Chronic Graft-Versus-Host Disease.
Front Immunol. 2018 Apr 4;9:656. doi: 10.3389/fimmu.2018.00656. eCollection 2018.
10
IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb.
J Immunol. 2006 Jul 1;177(1):306-14. doi: 10.4049/jimmunol.177.1.306.
引用本文的文献
1
Co-formulation of the rF1V plague vaccine with depot-formulated cytokines enhances immunogenicity and efficacy to elicit protective responses against aerosol challenge in mice.
Front Immunol. 2024 Mar 28;15:1277526. doi: 10.3389/fimmu.2024.1277526. eCollection 2024.
2
Insufficient phosphorylation of STAT5 in Tregs inhibits the expression of BLIMP-1 but not IRF4, reduction the proportion of Tregs in pediatric aplastic anemia.
Heliyon. 2024 Feb 29;10(5):e26731. doi: 10.1016/j.heliyon.2024.e26731. eCollection 2024 Mar 15.
3
IL-2-driven CD8 T cell phenotypes: implications for immunotherapy.
Trends Immunol. 2023 Nov;44(11):890-901. doi: 10.1016/j.it.2023.09.003. Epub 2023 Oct 10.
4
Regulatory T cells suppress the formation of potent KLRK1 and IL-7R expressing effector CD8 T cells by limiting IL-2.
Elife. 2023 Jan 27;12:e79342. doi: 10.7554/eLife.79342.
5
Interleukin-6 at the Host-Tumor Interface: STAT3 in Biomolecular Condensates in Cancer Cells.
Cells. 2022 Mar 30;11(7):1164. doi: 10.3390/cells11071164.
6
Influence of Different Age Cutoff Points on the Prediction of Prognosis of Cancer Patients Receiving ICIs and Potential Mechanistic Exploration.
Front Oncol. 2021 Jun 23;11:670927. doi: 10.3389/fonc.2021.670927. eCollection 2021.
7
CD122-targetted IL-2 signals cause acute and selective apoptosis of B cells in Peyer's Patches.
Sci Rep. 2020 Jul 29;10(1):12668. doi: 10.1038/s41598-020-69632-5.
8
CD25-Targeted IL-2 Signals Promote Improved Outcomes of Influenza Infection and Boost Memory CD4 T Cell Formation.
J Immunol. 2020 Jun 15;204(12):3307-3314. doi: 10.4049/jimmunol.2000205. Epub 2020 May 6.
9
Escape or Fight: Inhibitors in Hemophilia A.
Front Immunol. 2020 Mar 24;11:476. doi: 10.3389/fimmu.2020.00476. eCollection 2020.
10
Polymicrobial sepsis influences NK-cell-mediated immunity by diminishing NK-cell-intrinsic receptor-mediated effector responses to viral ligands or infections.
PLoS Pathog. 2018 Oct 31;14(10):e1007405. doi: 10.1371/journal.ppat.1007405. eCollection 2018 Oct.
本文引用的文献
1
Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms.
Immunity. 2015 May 19;42(5):815-25. doi: 10.1016/j.immuni.2015.04.015.
2
IL-2: the first effective immunotherapy for human cancer.
J Immunol. 2014 Jun 15;192(12):5451-8. doi: 10.4049/jimmunol.1490019.
3
G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+Gr-1+ myeloid cells without compromising CD8+ T cell immune responses.
J Hematol Oncol. 2013 Oct 1;6:75. doi: 10.1186/1756-8722-6-75.
4
Fine epitope specificity of antibodies against interleukin-2 explains their paradoxical immunomodulatory effects.
MAbs. 2014 Jan 1;6(1):273-85. doi: 10.4161/mabs.27224. Epub 2013 Nov 19.
5
Human IL-2 mutein with higher antitumor efficacy than wild type IL-2.
J Immunol. 2013 Jun 15;190(12):6230-8. doi: 10.4049/jimmunol.1201895. Epub 2013 May 15.
6
Chimera of IL-2 linked to light chain of anti-IL-2 mAb mimics IL-2/anti-IL-2 mAb complexes both structurally and functionally.
ACS Chem Biol. 2013 May 17;8(5):871-6. doi: 10.1021/cb3007242. Epub 2013 Mar 5.
7
Deciphering the molecular bases of the biological effects of antibodies against Interleukin-2: a versatile platform for fine epitope mapping.
Immunobiology. 2013 Jan;218(1):105-13. doi: 10.1016/j.imbio.2012.02.009. Epub 2012 Feb 16.
8
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'.
Nature. 2012 Mar 25;484(7395):529-33. doi: 10.1038/nature10975.
9
The role of interleukin-2 during homeostasis and activation of the immune system.
Nat Rev Immunol. 2012 Feb 17;12(3):180-90. doi: 10.1038/nri3156.
10
Antitumor activity of IL-2/anti-IL-2 mAb immunocomplexes exerts synergism with that of N-(2-hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugate due to its low immunosuppressive activity.
Int J Cancer. 2011 Oct 15;129(8):2002-12. doi: 10.1002/ijc.25859. Epub 2011 Apr 13.
Zotero 插件